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The adaptor protein APPL2 inhibits insulin-stimulated glucose uptake through both Akt and  
its downstream target TBC1D1 in skeletal muscle
WD Zhu1, KKY Cheng1, B Chen1, Y Wang2, KSL Lam1, A Xu1,2
1Department of Medicine, The University of Hong Kong, Hong Kong
2Department of Pharmacology and Pharmacy, The University of Hong Kong, Hong Kong
introduction: APPL1 and APPL2 are the two intracellular adaptor proteins containing a PH domain, a PTB domain, 
and a Leucine zipper motif. Mounting evidence demonstrates that APPL1 is a positive regulator of insulin sensitivity 
by acting as a common relay of both adiponectin and insulin signalling pathways. However, the cellular functions of 
APPL2 and its relationships with APPL1 remain poorly understood. The objective of this study was to investigate the 
molecular relationships of APPL1 and APPL2 in insulin-mediated glucose uptake in skeletal muscle cells. 
Methods: Proteins physically associated with APPL1 or APPL2 are retained by affinity purification and co-
immunoprecipitation, followed by mass spectrometry–based proteomic identification. The effects of APPL1 and APPL2 
in regulating insulin signaling are measured by Akt phosphorylation and in-vitro or ex-vivo glucose uptake assay.
Results: APPL1 potentiates, but the Bar domain of APPL2 inhibits insulin-stimulated phosphorylation of the protein 
kinase Akt and subsequent glucose uptake in both skeletal muscles isolated from the transgenic mice and cultured 
myotubes. Proteomic analysis demonstrates that APPL2 but not APPL1 interacts with TBC1D1, which is a key player for 
contraction and insulin-stimulated glucose transport in skeletal muscle. Moreover, insulin stimulates the disassociation 
of APPL1 and APPL2 heterodimers, but facilitates the interaction of TBC1D1 with APPL2 through Akt activation. 
Furthermore, insulin-evoked binding of APPL2 with TBC1D1 on Serine 229 suppresses phosphorylation of TBC1D1 on 
Threonine 590, leading to further suppression of glucose uptake.
Conclusion: APPL1 and APPL2 act as a pair of ‘Yin-and-Yang’ regulators of insulin signalling and glucose uptake 
in skeletal muscle. APPL2 inhibits insulin-stimulated glucose uptake through its dual effects via the Bar domain on 
both APPL1 and TBC1D1. These findings shed new light on our understanding of the molecular mechanisms for the 
metabolic actions of insulin in skeletal muscle. 
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